Brazil CMO/CDMO Business Outlook from 2023 to 2033
The Brazil CMO/CDMO ecosystem is expected to surge at a CAGR of 2.7% in the forecast period 2023 to 2033. Its value is projected to increase from US$ 697.93 million in 2023 to US$ 907.67 million by 2033. The Brazil CMO/CDMO business was valued at US$ 679.10 million at the end of 2022 and is anticipated to exhibit a y-o-y growth of 2.8 % in 2023.
Attributes
Key Insights
Brazil CMO/CDMO Business Size (2022A)
US$ 679.10 million
Brazil CMO/CDMO Business Estimated Revenue (2023E)
US$ 697.93 million
Brazil CMO/CDMO Business Projected Revenue (2033F)
US$ 907.67 million
Value-based CAGR (2023 to 2033)
2.7%
Brazil is projected to be one of the most prominent pharmaceutical sectors in Latin America. The surging aging population, rising healthcare costs, and increased public knowledge of healthcare have all contributed to a steady increase in the demand for pharmaceuticals in Brazil.
The government of Brazil has implemented stringent rules to promote regional pharmaceutical production. This includes policies, including tax breaks and privileges for domestically produced goods.
The Brazil CMO/CDMO business has placed a substantial emphasis on the manufacturing of biologics and biosimilars. These sophisticated treatments frequently call for specialist production skills.
For contract manufacturing organizations (CMOs) and contract development and manufacturing organizations (CDMOs) operating in Brazil, compliance with international quality standards, such as Good Manufacturing Practices (GMP), is essential. Both domestic and international sales depend on compliance with regulatory regulations.
Biotech and pharmaceutical companies in Brazil are increasingly using CMOs and CDMOs to handle their manufacturing requirements. The necessity for flexible production capacity, access to specialist knowledge, and cost-effectiveness are a handful of the driving forces behind this outsourcing trend.
CMO/CDMO companies are set to offer manufacturing services to the biotechnology, pharmaceutical, and other industries, as well as help with the production of medical equipment. CMOs are also expected to provide their resources, knowledge, and facilities to make goods for their customers.
The CMO and CDMO sector has seen rapid expansion in recent years. The pharmaceutical and biotechnology industries have seen a rise in the outsourcing of production and development services owing to the advantages of cost savings, flexibility, and access to specialized knowledge.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
2018 to 2022 Brazil CMO/CDMO Space Analysis Vs. 2023 to 2033 Forecast
The Brazil CMO/CDMO business recorded a decent CAGR of 2.0% in the historical period from 2018 to 2022. The value for the CMO/CDMO business in Brazil was around 1.2% of the total US$ 56,660.60 million of the global CMO/CDMO business.
The growing pharmaceutical sector is the main factor spurring the Brazil CMO/CDMO business landscape. Increasing approval of manufacturing facilities is set to drive growth.
The total production capacity in Brazil rises as more manufacturing facilities are approved. The increased demand for outsourcing services would enable CMOs and CDMOs to take on additional clients and projects.
The approval of multiple manufacturing facilities, such as those for sterile injectables, biologics, or specialized formulations, can increase the variety of services provided by CMOs and CDMOs. Due to this variety, pharmaceutical companies can select partners who meet their particular requirements.
For instance, in August 2023, Granules India Limited achieved approval from the Brazilian Health Regulatory Agency (ANVISA) for its Bonthapally facility, located in Bonthapally Village, in recognition of its compliance with Good Manufacturing Practices guidelines.
Manufacturing facilities would become more competitive in the global business landscape as they receive approval. CMOs/CDMOs that can show compliance with international regulatory standards would draw clients from other nations looking for dependable manufacturing partners in addition to Brazil.
The Brazil CMO/CDMO ecosystem has begun to place a lot of emphasis on the manufacturing of biologics and biosimilars. The complexity of these products frequently necessitates specialized production capabilities, and this business category has seen tremendous expansion.
The government of Brazil has also started several programs to encourage expansion in the biotechnology and pharmaceutical sectors. These include tax breaks, research grants, and other forms of assistance to promote industrial investment and innovation.
CMOs and CDMOs in Brazil have started to focus more on research & development services and offering their experience in technological development. They are also aiming to understand analytical testing and process optimization in addition to typical manufacturing services
Trends, Opportunities, and Challenges in Brazil CMO/CDMO Space
The table below provides the latest trends observed in the Brazil CMO/CDMO space, growth obstacles, and upcoming opportunities. Business strategies for pushing CMO/CDMO sales in Brazil would enable stakeholders to invest in the right area and gain profit.
Attributes
Key Factors
Latest Trends
Pharmaceutical and biotechnology companies are progressively outsourcing their manufacturing requirements to CMOs and CDMOs. This trend is driven by aspects such as cost efficiency, access to expert knowledge, and the need for flexible manufacturing capabilities.
Biologics and biosimilar manufacturing is a rising segment in the Brazil CMO/CDMO business. This is due to the growing demand for these compound therapies, which often need specialized manufacturing abilities.
Regulatory acquiescence and adherence to global quality standards remain important aspects for both CMOs and CDMOs. Companies have focused on upholding high-quality manufacturing processes to meet worldwide regulatory requirements.
CMOs and CDMOs are capitalizing on advanced technology and automation to increase efficiency, reduce costs, and improve the quality of the manufacturing process. This includes the adoption of advanced manufacturing systems and equipment.
Environmental sustainability has become a significant consideration in the CMO/CDMO space. Businesses are adopting environmentally friendly methods and technologies to diminish their impact on the environment and align with global sustainable development goals.
Upcoming Opportunities
High-quality manufacturing by CMO/CDMOs can create a lucrative opportunity in the Brazil CMO/CDMO business. Pharmaceutical companies in Brazil can gain from luring foreign customers looking for partners with a reputation for top-notch production.
Customers from all around the world support CMOs/CDMOs that can reliably create pharmaceuticals that adhere to global quality standards, such as Good Manufacturing Practices (GMP), thereby creating new opportunities in Brazil.
In a competitive sector, superior manufacturing sets CMOs/CDMOs in particular. The assurance of product quality and safety is valued by companies searching for outsourcing partners, and they are willing to pay more for such services.
Pharmaceutical companies that outsource manufacturing aim to reduce risks related to supply chain interruptions, product quality, and regulatory compliance. Reducing these risks involves collaborating with CMOs/CDMOs recognized for high-quality production.
Specializing in specific therapeutic areas is the reason for boosting the CMO/CDMO demand in Brazil over the forecast period. Utilizing their experience and expertise, specialized CMOs/CDMOs can accelerate the drug development process. This is expected to result in shorter development cycles, which can hasten the time it takes for pharmaceutical businesses to sell their drugs.
Challenges
The Brazil CMO/CDMO business faces a significant restraint in the form of quality assurance, compliance challenges, and supply chain vulnerabilities. The regulatory environment in Brazil frequently necessitates significant documentation through records of production operations and quality control procedures. It can be time- and resource-consuming to ensure accurate and detailed documentation.
It is possible that smaller CMOs/CDMOs in Brazil will run into resource issues while attempting to build and maintain effective quality assurance and compliance procedures. Their capacity to compete with bigger, more seasoned players can be limited as a result.
Regular compliance inspections by regulatory bodies can hinder productivity and take resources away from it. Findings of non-compliance can result in fines, such as halts in production.
Dependence on imported raw materials and active pharmaceutical ingredients (APIs) can put CMOs and CDMOs at risk for supply interruptions brought on by factors, including trade restrictions, transportation problems, or shifts in the dynamics of the world's supply chain.
Find your sweet spots for generating winning opportunities in this market.
Comparative View of Adjacent Brazil CMO/CDMO Businesses
The section covers a comparative view of three businesses similar to the global Brazil CMO/CDMO business. As per estimations, the small molecule innovator CDMO space would lead out of the three businesses.
The Brazil CMO/CDMO business is set to reach a valuation of US$ 697.93 million by 2023. The small molecule innovator, CDMO, and CMO/CDMO businesses are projected to reach US$ 48.09 billion and US$ 22.5 billion, respectively, in 2023.
Key Trends in the Brazil CMO/CDMO Business Landscape:
CAGR (2023 to 2033)
2.7%
Estimated Value (2023)
US$ 697.93 million
Growth Factor
CMOs and CDMOs are collaborating strategically with biotech start-ups, pharmaceutical corporations, and academic institutions. These partnerships are set to help create and produce pharmaceutical goods by utilizing their combined knowledge, resources, and capabilities.
Key Trend
The CMO/CDMO ecosystem is trending toward consolidation, with larger organizations purchasing smaller, specialized businesses to expand their service portfolios and geographic reach.
Factors Pushing CMO/CDMO Demand :
CAGR (2023 to 2033)
5.7%
Estimated Value (2023)
US$ 22.5 billion
Growth Factor
Through acquisitions and acquisitions, the Business has experienced a high level of consolidation. To increase their service offerings and geographic reach, larger CDMOs are purchasing smaller, specialized businesses.
Key Trend
Due to their potential to completely change the way healthcare is provided, the development and production of ATMPs, such as gene therapies, cell therapies, and tissue-engineered products, have received particular attention.
Opportunities in the Small Molecule Innovator CDMO Space:
CAGR (2023 to 2033)
6.4%
Estimated Value (2023)
US$ 48.09 billion
Growth Factor
To improve data integrity, traceability, and transparency throughout the manufacturing process, innovative CDMOs are investing in digital technology and data management systems.
Key Trend
Adopting green chemistry concepts and sustainable manufacturing techniques is becoming more and more important. This entails limiting waste, conserving energy, and utilizing more eco-friendly solvents.
Region-wise Insights
The table below shows the share of the top 5 countries for the review period from 2023 to 2033. South and North Brazil are expected to remain dominant by exhibiting CAGRs of 4.5% and 4.9%, respectively. The Central-west and Northeast Brazil are projected to follow with CAGRs of 3.8% and 3.1%, respectively.
Growth Outlook by Key Region
Regions
Value CAGR
Southeast Brazil
2.3%
Northeast Brazil
3.1%
Central-west Brazil
3.8%
South Brazil
4.5%
North Brazil
4.9%
Increasing Research and Development in Southeast Brazil to Drive Demand
Growth in Southeast Brazil’s pharmaceutical sector is expanding steadily. Due to population expansion and improved access to healthcare, there is an increase in local demand for pharmaceuticals and other medical products.
The Southeast area of Brazil is benefiting from initiatives the government has put in place to encourage pharmaceutical business expansion. This includes financial incentives and tax breaks for businesses setting up shop in the region.
Southeast Brazil dominated the CMO/CDMO business and generated a 68.6% share in 2022. It is projected to continue experiencing high growth throughout the forecast period.
The economic center of Brazil is in the southeast, which is home to important cities, such as Sao Paulo and Rio de Janeiro. It is a popular site for CMOs and CDMOs to serve these clients because of its significant industrial base and the large number of pharmaceutical and biotech companies that call it home.
Prestigious universities and research institutions in Southeast Brazil offer a skilled labor pool and chances for collaboration between CMOs/CDMOs and academia on research & development projects. Also, several CMOs/CDMOs based in Southeast Brazil have expanded their operations globally, enabling them to serve clients both domestically and internationally.
Increasing Focus on Biotechnology to Surge Demand in Northeast Brazil
A handful of states in Northeast Brazil, such as Pernambuco, have taken special initiatives to draw in investments in the fields of biotechnology and life sciences. This has caused a cluster of biotech businesses to expand, opening doors for CMOs and CDMOs that focus on biologics.
Biotechnology and pharmaceutical research and development have received more attention in the region. This involves the development of formulations, analytical testing, and process optimization, areas in which CMOs and CDMOs can be particularly skilled.
Northeast Brazil dominates the Brazil CMO/CDMO business and held a 19.8% share in 2022. It is projected to continue experiencing high growth throughout the forecast period. Northeast Brazil has special environmental features or natural resources that make biopharmaceutical research and development possible.
Northeast Brazil is also the perfect location for companies focused on biotech and their manufacturing partners backed by these resources. Also, the region is home to eminent research facilities and academic hubs with a focus on biotechnology and pharmaceuticals.
They can promote cooperation between these institutions and CMOs/CDMOs. Such collaborations are frequently necessary to expand research and development initiatives.
Rising Investments in Infrastructure Fuel Sales in Central-west Brazil
Central-west Brazil held about a 5.1% share of the Brazil CMO/CDMO business in 2022. It is projected to increase during the forecast period.
Central-west Brazil's center geographic location offers a logistical advantage, enabling effective pharmaceutical product distribution to multiple regions across Brazil and adjacent nations. For CMOs and CDMOs aiming to serve a large space, this can be a crucial draw.
Investments in infrastructure, including transportation networks and industrial parks, can further enhance the region's attractiveness for pharmaceutical manufacturing and supply chain operations. The government supports domestic medicinal product production.
CMOs and CDMOs in the region would have the chance to serve the home ecosystem and export goods. Several colleges and research facilities in Central-west Brazil offer a pool of qualified workers in fields related to pharmaceutical development and manufacturing. CMOs and CDMOs can benefit from this in terms of hiring new personnel.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need and save 40%!
Category-wise Insights
The table below signifies leading sub-categories under product, expression, and company size categories in the Brazil CMO/CDMO business. Stand-alone services are expected to dominate the ecosystem for Brazil CMO/CDMO at a CAGR of 3.4% by 2033. Under the company size category, the mid-sized segment is projected to lead the Brazil CMO/CDMO space with a CAGR of 2.3% by 2033.
Growth Outlook by Key Segments
Segment
Value CAGR
Stand-alone Services (Services)
3.4%
API Substrate (Product)
1.9%
Mid-sized (Company Size)
2.3%
Mammalian (Expression System)
2.7%
Commercial (Scale of Operation)
2.9%
Stand-alone Services are to be Preferred Amid High Cost-cutting Needs
Stand-alone services under the service category held a share of 42.5% in 2022. It is expected to remain at the forefront over the forecast period.
Stand-alone services focus on specific aspects of drug development and manufacturing, such as formulation development, analytical testing, or sterile manufacturing. This specialization can attract companies seeking expertise in a particular area.
Companies decide to use stand-alone services to cut costs by outsourcing only a portion of the production or development of drugs while maintaining control over the remaining portions. This factor is anticipated to lead the stand-alone service segment in the Brazil CMO/CDMO business.
API Substrates are the Most Popular Type of Product
API substrate under the product category held a considerable share of 41.4% in 2022. The main components of pharmaceutical formulations are APIs.
APIs, often referred to as the dynamic components of medications, underlie their therapeutic effectiveness. The process of crafting APIs holds a pivotal role in the production of pharmaceuticals, marking a critical step in the journey of creating therapeutic solutions.
Pharmaceutical companies find it more affordable to outsource API production. The volume and efficiency of CMOs and CDMOs would allow them to create APIs more cheaply than in-house labs.
Mammalian Expression Systems to be Chosen Primarily by Suppliers
For the manufacturing of biologics, such as monoclonal antibodies, recombinant proteins, and vaccines, mammalian expression systems are frequently chosen. Due to their success in treating a wide range of ailments, biologics have grown in terms of popularity in the operating of the pharmaceutical sector.
Mammalian expression systems are set to be necessary for the manufacturing of several advanced and sophisticated medicines, including cell and gene therapies. These treatments are projected to make up a rapidly expanding area for pharmaceuticals. This factor is expected to stimulate the mammalian segment over the forecast timeline.
Competitive Landscape
Geographic expansions are a priority for leading CMO/CDMO companies in Brazil as they work to create new product lines and expand their global consumer base. Expansion and acquisition among key companies or brands is the leading strategy of manufacturers such as Catalent and Fragon.
They aim to enhance their presence in the business landscape and compete with other players during the forecast period. Following are a handful of recent developments:
For instance,
In May 2021, Lonza inaugurated a new laboratory, marking a significant step in the Swiss Contract Development and Manufacturing Organization's (CDMO) strategy to bolster its presence in North America. It also plans to advance its Early Development Services (EDS) segment.
In February 2022, Pharma Nobis, LLC completed its acquisition of Fagron’s contract manufacturing business and manufacturing facility.
In August 2022, Catalent made an announcement regarding its acquisition of Metrics Contract Services. Metrics Contract Services is a specialized Contract Development and Manufacturing Organization (CDMO) known for its 333,000-square-foot facility located in Greenville.
Report Scope
Attribute
Details
Brazil CMO-CDMO Revenue (2022)
US$ 679.10 million
Projected Brazil CMO-CDMO Revenue (2033)
US$ 907.67 million
Value-based CAGR (2023 to 2033)
2.7%
Forecast Period
2023 to 2033
Historical Data Available for
2018 to 2022
Business Analysis
Value (US$ million)
Key Regions Covered
North Brazil, Northeast Brazil, Central-west Brazil, Southeast Brazil, and South Brazil
Key Segments Covered
Services
Product
Expression System
Company Size
Scale of Operation
Region
Key Companies Profiled
Lonza AG
Unither Pharmaceuticals
Catalent Inc.
Fagron
Eurofarma
Pfizer CentreOne
Patheon N.V. (Thermo Fisher Scientific, Inc.)
NUVISAN
Societal CDMO
Bio-Manguinhos
Biotimize
Pierre Fabre group
Ajinomoto Co., Inc.
Brazil CMO/CDMO Industry Outlook by Category
By Services:
Stand-alone Services
Cell Line Development
Development and Bio Manufacturing
Analytical Services
Fill Finish
Packaging
Clinical Supply Services
Integrated Development
Scale-up and Tech Transfer
Technology and Innovation
Quality Control and Quality Assurance
Regulatory Assistance
By Product:
API Substrate
Large Molecule
Monoclonal Antibodies
Antibody Fragments
Recombinant Therapeutic Proteins
Viral Vector
Cell and Gene Therapy
Vaccine
Peptides
Antibody Drug Conjugates (ADCs)
Small Molecule
By Expression System:
Mammalian
Microbial
Bacteria
Yeast
By Company Size:
Small
Mid-sized
Large
Very Large
By Scale of Operation:
Preclinical
Clinical
Phase I
Phase II
Phase III
Commercial
By Region:
North Brazil
Northeast Brazil
Central-west Brazil
Southeast Brazil
South Brazil
Frequently Asked Questions
How large was the Brazil CMO/CDMO ecosystem in 2022?
Brazil was valued at around US$ 679.10 million in 2022.
What is the Brazil CMO/CDMO ecosystem projected value for 2033?
Brazil is set to reach a valuation of around US$ 907.67 million by 2033.
Which product segment is set to lead the Brazil CMO/CDMO business?
The API substrate segment held around 41.4% share in 2022.
What was the historical CAGR for the Brazil CMO/CDMO space?
Brazil's CMO/CDMO space increased at a 2.0% CAGR from 2018 to 2022.
What value is the Brazil CMO/CDMO business estimated to reach by 2023?
The Brazil CMO/CDMO business is set to reach US$ 697.93 million by 2023.
What is the Southeast Brazil CMO/CDMO space outlook?
Southeast Brazil CMO/CDMO business held a 68.6% share in 2022.
Which are the leading companies in Brazil's CMO/CDMO business?
Lonza AG and Unither Pharmaceuticals are the key exporters of CMO/CDMO in Brazil.
Table of Content
1. Executive Summary
1.1. Outlook
1.2. Demand Side Trends
1.3. Supply-Side Trends
1.4. Analysis and Recommendations
2. Overview
2.1. Coverage / Taxonomy
2.2. Definition / Scope / Limitations
2.3. Inclusions and Exclusions
3. Key Trends
3.1. Key Trends
4. Value Added Insights
4.1. Service Adoption Analysis/Usage Analysis
4.2. Overview of CRO and CDMO Services
4.3. Role of Contract Service Providers
4.4. Overview of CDMO with a Wide Array of Dosage Form Capabilities
4.5. Regulatory Scenario
4.6. Latest Deals
4.7. PESTLE Analysis
4.8. Porter’s Analysis
4.9. Pharma Services Supply Chain Analysis
4.10. Value Chain Analysis
5. Background
5.1. Macro-Economic Factors
5.1.1. GDP Growth Outlook
5.1.2. Research and Development Funding by Region
5.1.3. Research and Development Funding by Country
5.1.4. Pharmaceutical Spending, By Country
5.1.5. Global CMO-CDMO Sales
5.2. Forecast Factors - Relevance and Impact
5.2.1. Historic Growth of Key Players
5.2.2. Consolidation Activities
5.2.3. Increasing Research and Development Activities
5.2.4. Increased Funding and Support from Government
5.2.5. CMO/CDMO Services Adoption Rates
5.2.6. Increasing Number of Diagnostics Testing and Development
5.2.7. Regulatory Imposition
5.2.8. Increase in Number of Clinicians and Specialists
5.3. Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity Analysis
6. Demand Value or Size (US$ million) Analysis 2018 to 2022 and Forecast, 2023 to 2033
6.1. Historical Value (US$ million) Analysis, 2018 to 2022
6.2. Current and Future Value (US$ million) Projections, 2023 to 2033
6.2.1. Y-o-Y Growth Trend Analysis
6.2.2. Absolute $ Opportunity Analysis
7. Sales Analysis 2018 to 2022 and Forecast 2023 to 2033, By Services
7.1. Introduction / Key Findings
7.2. Historical Size (US$ million) Analysis By Services, 2018 to 2022
7.3. Current and Future Size (US$ million) Analysis and Forecast By Services, 2023 to 2033
7.3.1. Stand-Alone Services
7.3.1.1. Cell Line Development
7.3.1.2. Development and Bio Manufacturing
7.3.1.3. Analytical Services
7.3.1.4. Fill Finish
7.3.1.5. Packaging
7.3.1.6. Clinical Supply Services
7.3.2. Integrated Development
7.3.3. Scale-up and Tech Transfer
7.3.4. Technology and Innovation
7.3.5. Quality Control and Quality Assurance
7.3.6. Regulatory Assistance
7.4. Attractiveness Analysis By Services
8. Sales Analysis 2018 to 2022 and Forecast 2023 to 2033, By Product
8.1. Introduction / Key Findings
8.2. Historical Size (US$ million) By Product, 2018 to 2022
8.3. Current and Future Size (US$ million) Analysis and Forecast By Product, 2023 to 2033
8.3.1. API Substrate
8.3.2. Large Molecule
8.3.2.1. Monoclonal Antibodies
8.3.2.2. Antibody Fragments
8.3.2.3. Recombinant Therapeutic Proteins
8.3.2.4. Viral Vector
8.3.2.5. Cell and Gene Therapy
8.3.2.6. Vaccine
8.3.2.7. Peptides
8.3.2.8. Antibody Drug Conjugates (ADCs)
8.3.3. Small Molecule
8.4. Attractiveness Analysis By Product
9. Sales Analysis 2018 to 2022 and Forecast 2023 to 2033, By Expression System
9.1. Introduction / Key Findings
9.2. Historical Size (US$ million) By Expression System, 2018 to 2022
9.3. Current and Future Size (US$ million) Analysis and Forecast By Expression System, 2023 to 2033
9.3.1. Mammalian
9.3.2. Microbial
9.3.2.1. Bacteria
9.3.2.2. Yeast
9.4. Attractiveness Analysis By Expression System
10. Sales Analysis 2018 to 2022 and Forecast 2023 to 2033, By Company Size
10.1. Introduction / Key Findings
10.2. Historical Size (US$ million) By Company Size, 2018 to 2022
10.3. Current and Future Size (US$ million) Analysis and Forecast By Company Size, 2023 to 2033
10.3.1. Small
10.3.2. Mid-sized
10.3.3. Large
10.3.4. Very Large
10.4. Attractiveness Analysis By Company Size
11. Sales Analysis 2018 to 2022 and Forecast 2023 to 2033, By Scale of Operation
11.1. Introduction / Key Findings
11.2. Historical Size (US$ million) By Scale of Operation, 2018 to 2022
11.3. Current and Future Size (US$ million) Analysis and Forecast By Scale of Operation, 2023 to 2033
11.3.1. Preclinical
11.3.2. Clinical
11.3.2.1. Phase I
11.3.2.2. Phase II
11.3.2.3. Phase III
11.3.3. Commercial
11.4. Attractiveness Analysis By Scale of Operation
12. Sales Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
12.1. Introduction
12.2. Historical Size (US$ million) Trend Analysis by Region, 2018 to 2022
12.3. Current and Future Size (US$ million) Analysis and Forecast by Region, 2023 to 2033
12.3.1. North
12.3.2. Northeast
12.3.3. Central-west
12.3.4. Southeast
12.3.5. South
12.4. Attractiveness Analysis By Region
13. Business: Cross Section Analysis-Product Vs Services
13.1. Historical Size (US$ million) Trend Analysis by Product Vs Services, 2018 to 2022
13.2. Current and Future Size (US$ million) Analysis and Forecast by Product Vs Services, 2023 to 2033
13.2.1. API Substrate
13.2.1.1. Stand-Alone Services
13.2.1.2. Integrated Development
13.2.1.3. Scale-Up and Tech Transfer
13.2.1.4. Technology and Innovation
13.2.1.5. Quality Control and Quality Assurance
13.2.1.6. Regulatory Assistance
13.2.2. Large Molecule
13.2.2.1. Stand-Alone Services
13.2.2.2. Integrated Development
13.2.2.3. Scale-Up and Tech Transfer
13.2.2.4. Technology and Innovation
13.2.2.5. Quality Control and Quality Assurance
13.2.2.6. Regulatory Assistance
13.2.3. Small Molecule
13.2.3.1. Stand-Alone Services
13.2.3.2. Integrated Development
13.2.3.3. Scale-Up and Tech Transfer
13.2.3.4. Technology and Innovation
13.2.3.5. Quality Control and Quality Assurance
13.2.3.6. Regulatory Assistance
14. North Sales Analysis 2018 to 2022 and Forecast 2023 to 2033
14.1. Introduction
14.2. Historical Size (US$ million) Analysis Trend Analysis by Taxonomy, 2018 to 2022
14.3. Current and Future Size (US$ million) Analysis and Forecast by Taxonomy, 2023 to 2033
14.3.1. By Service
14.3.2. By Product
14.3.3. By Expression System
14.3.4. By Company
14.3.5. By Scale of Operation
14.4. Attractiveness Analysis
14.4.1. By Service
14.4.2. By Product
14.4.3. By Expression System
14.4.4. By Company
14.4.5. By Scale of Operation
14.5. Drivers and Restraints - Impact Analysis
15. Northeast Sales Analysis 2018 to 2022 and Forecast 2023 to 2033
15.1. Introduction
15.2. Historical Size (US$ million) Trend Analysis by Taxonomy, 2018 to 2022
15.3. Current and Future Size (US$ million) Analysis and Forecast by Taxonomy, 2023 to 2033
15.3.1. By Service
15.3.2. By Product
15.3.3. By Expression System
15.3.4. By Company
15.3.5. By Scale of Operation
15.4. Attractiveness Analysis
15.4.1. By Service
15.4.2. By Product
15.4.3. By Expression System
15.4.4. By Company
15.4.5. By Scale of Operation
15.5. Drivers and Restraints - Impact Analysis
16. Central-west Sales Analysis 2018 to 2022 and Forecast 2023 to 2033
16.1. Introduction
16.2. Historical Size (US$ million) Trend Analysis by Taxonomy, 2018 to 2022
16.3. Current and Future Size (US$ million) Analysis and Forecast by Taxonomy, 2023 to 2033
16.3.1. By Service
16.3.2. By Product
16.3.3. By Expression System
16.3.4. By Company
16.3.5. By Scale of Operation
16.4. Attractiveness Analysis
16.4.1. By Service
16.4.2. By Product
16.4.3. By Expression System
16.4.4. By Company
16.4.5. By Scale of Operation
16.5. Drivers and Restraints - Impact Analysis
17. Southeast Sales Analysis 2018 to 2022 and Forecast 2023 to 2033
17.1. Introduction
17.2. Historical Size (US$ million) Trend Analysis by Taxonomy, 2018 to 2022
17.3. Current and Future Size (US$ million) Analysis and Forecast by Taxonomy, 2023 to 2033
17.3.1. By Service
17.3.2. By Product
17.3.3. By Expression System
17.3.4. By Company
17.3.5. By Scale of Operation
17.4. Attractiveness Analysis
17.4.1. By Service
17.4.2. By Product
17.4.3. By Expression System
17.4.4. By Company
17.4.5. By Scale of Operation
17.5. Drivers and Restraints - Impact Analysis
18. South Sales Analysis 2018 to 2022 and Forecast 2023 to 2033
18.1. Introduction
18.2. Historical Size (US$ million) Trend Analysis by Taxonomy, 2018 to 2022
18.3. Current and Future Size (US$ million) Analysis and Forecast by Taxonomy, 2023 to 2033
18.3.1. By Service
18.3.2. By Product
18.3.3. By Expression System
18.3.4. By Company
18.3.5. By Scale of Operation
18.4. Attractiveness Analysis
18.4.1. By Service
18.4.2. By Product
18.4.3. By Expression System
18.4.4. By Company
18.4.5. By Scale of Operation
18.5. Drivers and Restraints - Impact Analysis
19. State Level Sales Analysis 2022 and Forecast 2033
19.1. Rio de Janeiro CMO/CDMO Analysis
19.1.1. Introduction
19.1.2. Sales Analysis and Forecast by Taxonomy
19.1.2.1. By Service
19.1.2.2. By Product
19.1.2.3. By Expression System
19.1.2.4. By Company
19.1.2.5. By Scale of Operation
19.2. São Paulo CMO/CDMO Analysis
19.2.1. Introduction
19.2.2. Sales Analysis and Forecast by Taxonomy
19.2.2.1. By Service
19.2.2.2. By Product
19.2.2.3. By Expression System
19.2.2.4. By Company
19.2.2.5. By Scale of Operation
19.3. Minas Geras CMO/CDMO Analysis
19.3.1. Introduction
19.3.2. Sales Analysis and Forecast by Taxonomy
19.3.2.1. By Service
19.3.2.2. By Product
19.3.2.3. By Expression System
19.3.2.4. By Company
19.3.2.5. By Scale of Operation
19.4. Bahia CMO/CDMO Analysis
19.4.1. Introduction
19.4.2. Sales Analysis and Forecast by Taxonomy
19.4.2.1. By Service
19.4.2.2. By Product
19.4.2.3. By Expression System
19.4.2.4. By Company
19.4.2.5. By Scale of Operation
19.5. Pioui CMO/CDMO Analysis
19.5.1. Introduction
19.5.2. Sales Analysis and Forecast by Taxonomy
19.5.2.1. By Service
19.5.2.2. By Product
19.5.2.3. By Expression System
19.5.2.4. By Company
19.5.2.5. By Scale of Operation
19.6. Rest of CMO/CDMO Analysis
19.6.1. Introduction
19.6.2. Sales Analysis and Forecast by Taxonomy
19.6.2.1. By Service
19.6.2.2. By Product
19.6.2.3. By Expression System
19.6.2.4. By Company
19.6.2.5. By Scale of Operation
20. Structure Analysis
20.1. Sales Analysis by Tier of Companies
20.2. Share Analysis of Top Players (%)
21. Competition Analysis
21.1. Competition Dashboard
21.2. Competition Benchmarking
21.3. Key Development Analysis
21.4. Branding and Promotional Strategies, by Key Manufacturers
21.5. Competition Deep Dive
21.5.1. Lonza AG
21.5.1.1. Overview
21.5.1.2. Product Portfolio
21.5.1.3. Key Financials
21.5.1.4. SWOT Analysis
21.5.1.5. Key Developments
21.5.1.6. Sales Footprint
21.5.1.7. Strategy Overview
21.5.2. Lonza AG
21.5.2.1. Overview
21.5.2.2. Product Portfolio
21.5.2.3. Key Financials
21.5.2.4. SWOT Analysis
21.5.2.5. Key Developments
21.5.2.6. Sales Footprint
21.5.2.7. Strategy Overview
21.5.3. Unither Pharmaceuticals
21.5.3.1. Overview
21.5.3.2. Product Portfolio
21.5.3.3. Key Financials
21.5.3.4. SWOT Analysis
21.5.3.5. Key Developments
21.5.3.6. Sales Footprint
21.5.3.7. Strategy Overview
21.5.4. Catalent Inc.
21.5.4.1. Overview
21.5.4.2. Product Portfolio
21.5.4.3. Key Financials
21.5.4.4. SWOT Analysis
21.5.4.5. Key Developments
21.5.4.6. Sales Footprint
21.5.4.7. Strategy Overview
21.5.5. Fagron
21.5.5.1. Overview
21.5.5.2. Product Portfolio
21.5.5.3. Key Financials
21.5.5.4. SWOT Analysis
21.5.5.5. Key Developments
21.5.5.6. Sales Footprint
21.5.5.7. Strategy Overview
21.5.6. Eurofarma
21.5.6.1. Overview
21.5.6.2. Product Portfolio
21.5.6.3. Key Financials
21.5.6.4. SWOT Analysis
21.5.6.5. Key Developments
21.5.6.6. Sales Footprint
21.5.6.7. Strategy Overview
21.5.7. Pfizer CentreOne
21.5.7.1. Overview
21.5.7.2. Product Portfolio
21.5.7.3. Key Financials
21.5.7.4. SWOT Analysis
21.5.7.5. Key Developments
21.5.7.6. Sales Footprint
21.5.7.7. Strategy Overview
21.5.8. Patheon N.V. (Thermo Fisher Scientific, Inc.)
21.5.8.1. Overview
21.5.8.2. Product Portfolio
21.5.8.3. Key Financials
21.5.8.4. SWOT Analysis
21.5.8.5. Key Developments
21.5.8.6. Sales Footprint
21.5.8.7. Strategy Overview
21.5.9. NUVISAN
21.5.9.1. Overview
21.5.9.2. Product Portfolio
21.5.9.3. Key Financials
21.5.9.4. SWOT Analysis
21.5.9.5. Key Developments
21.5.9.6. Sales Footprint
21.5.9.7. Strategy Overview
21.5.10. Societal CDMO
21.5.10.1. Overview
21.5.10.2. Product Portfolio
21.5.10.3. Key Financials
21.5.10.4. SWOT Analysis
21.5.10.5. Key Developments
21.5.10.6. Sales Footprint
21.5.10.7. Strategy Overview
21.5.11. Bio-Manguinhos
21.5.11.1. Overview
21.5.11.2. Product Portfolio
21.5.11.3. Key Financials
21.5.11.4. SWOT Analysis
21.5.11.5. Key Developments
21.5.11.6. Sales Footprint
21.5.11.7. Strategy Overview
21.5.12. Biotimize
21.5.12.1. Overview
21.5.12.2. Product Portfolio
21.5.12.3. Key Financials
21.5.12.4. SWOT Analysis
21.5.12.5. Key Developments
21.5.12.6. Sales Footprint
21.5.12.7. Strategy Overview
21.5.13. Pierre Fabre group
21.5.13.1. Overview
21.5.13.2. Product Portfolio
21.5.13.3. Key Financials
21.5.13.4. SWOT Analysis
21.5.13.5. Key Developments
21.5.13.6. Sales Footprint
21.5.13.7. Strategy Overview
21.5.14. Ajinomoto Co., Inc.
21.5.14.1. Overview
21.5.14.2. Product Portfolio
21.5.14.3. Key Financials
21.5.14.4. SWOT Analysis
21.5.14.5. Key Developments
21.5.14.6. Sales Footprint
21.5.14.7. Strategy Overview
22. Assumptions and Acronyms Used
List of Tables
Table 01: Size (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Services
Table 02: Size (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Product
Table 03: Size (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Expression System
Table 04: Size (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Company Size
Table 05: Size (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Scale of Operation
Table 06: Size (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
Table 07: Business, Cross Sectional Analysis of Product Vs Services, 2018 to 2033
Table 08: Business, Cross Sectional Analysis of Product Vs Services, 2018 to 2033
Table 09: Business, Cross Sectional Analysis of Product Vs Services, 2018 to 2033
Table 10: North Size (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Services
Table 11: North Size (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Product
Table 12: North Size (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Expression System
Table 13: North Size (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Company Size
Table 14: North Size (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Scale of Operation
Table 15: Northeast Size (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Services
Table 16: Northeast Size (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Product
Table 17: Northeast Size (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Expression System
Table 18: Northeast Size (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Company Size
Table 19: Northeast Size (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Scale of Operation
Table 20: Central-West Size (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Services
Table 21: Central-West Size (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Product
Table 22: Central-West Size (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Expression System
Table 23: Central-West Size (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Company Size
Table 24: Central-West Size (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Scale of Operation
Table 25: Southeast Size (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Services
Table 26: Southeast Size (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Product
Table 27: Southeast Size (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Expression System
Table 28: Southeast Size (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Company Size
Table 29: Southeast Size (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Scale of Operation
Table 30: South Size (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Services
Table 31: South Size (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Product
Table 32: South Size (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Expression System
Table 33: South Size (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Company Size
Table 34: South Size (US$ million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Scale of Operation
List of Charts
Figure 01: Split By Region, 2023 (E)
Figure 02: Split By Services, 2023 (E)
Figure 03: Split By Product, 2023 (E)
Figure 04: Split By Expression System, 2023 (E)
Figure 05: Split By Company Size, 2023 (E)
Figure 06: Split By Scale of Operation, 2023 (E)
Figure 07: Historical Value (US$ million) Analysis, 2018 to 2022
Figure 08: Value (US$ million), 2023 to 2033 & Y-o-Y Growth Trend Analysis
Figure 09: Absolute $ Opportunity, 2023 to 2033
Figure 10: Share Analysis (%) By Services, 2023 to 2033
Figure 11: Y-o-Y Growth (%) By Services, 2023 to 2033
Figure 12: Attractiveness Analysis, By Services
Figure 13: Share Analysis (%) By Product, 2023 to 2033
Figure 14: Y-o-Y Growth (%) By Product, 2023 to 2033
Figure 15: Attractiveness Analysis, By Product
Figure 16: Share Analysis (%) By Expression System, 2023 to 2033
Figure 17: Y-o-Y Growth (%) By Expression System, 2023 to 2033
Figure 18: Attractiveness Analysis, By Expression System
Figure 19: Share Analysis (%) By Company Size, 2023 to 2033
Figure 20: Y-o-Y Growth (%) By Company Size 2023 to 2033
Figure 21: Attractiveness Analysis, By Company Size
Figure 22: Share Analysis (%) By Scale of Operation, 2023 to 2033
Figure 23: Y-o-Y Growth (%) By Scale of Operation, 2023 to 2033
Figure 24: Attractiveness Analysis, By Scale of Operation
Figure 25: Share Analysis (%) By Region, 2023 to 2033
Figure 26: Y-o-Y Growth (%) By Region, 2023 to 2033
Figure 27: Attractiveness Analysis, By Region
Figure 28: North Split By Services, 2023 (E)
Figure 29: North Split By Product, 2023 (E)
Figure 30: North Split By Expression System, 2023 (E)
Figure 31: North Split By Company Size, 2023 (E)
Figure 32: North Split By Scale of Operation, 2023 (E)
Figure 33: North Historical Value (US$ million) Analysis, 2018 to 2022
Figure 34: North Value (US$ million), 2023 to 2033 & Y-o-Y Growth Trend Analysis
Figure 35: North Attractiveness Analysis, By Services
Figure 36: North Attractiveness Analysis, By Product
Figure 37: North Attractiveness Analysis, By Expression System
Figure 38: North Attractiveness Analysis, By Company Size
Figure 39: North Attractiveness Analysis, By Scale of Operation
Figure 40: Northeast Split By Services, 2023 (E)
Figure 41: Northeast Split By Product, 2023 (E)
Figure 42: Northeast Split By Expression System, 2023 (E)
Figure 43: Northeast Split By Company Size, 2023 (E)
Figure 44: Northeast Split By Scale of Operation, 2023 (E)
Figure 45: Northeast Historical Value (US$ million) Analysis, 2018 to 2022
Figure 46: Northeast Value (US$ million), 2023 to 2033 & Y-o-Y Growth Trend Analysis
Figure 47: Northeast Attractiveness Analysis, By Services
Figure 48: Northeast Attractiveness Analysis, By Product
Figure 49: Northeast Attractiveness Analysis, By Expression System
Figure 50: Northeast Attractiveness Analysis, By Company Size
Figure 51: Northeast Attractiveness Analysis, By Scale of Operation
Figure 52: Central-West Split By Services, 2023 (E)
Figure 53: Central-West Split By Product, 2023 (E)
Figure 54: Central-West Split By Expression System, 2023 (E)
Figure 55: Central-West Split By Company Size, 2023 (E)
Figure 56: Central-West Split By Scale of Operation, 2023 (E)
Figure 57: Central-West Historical Value (US$ million) Analysis, 2018 to 2022
Figure 58: Central-West Value (US$ million), 2023 to 2033 & Y-o-Y Growth Trend Analysis
Figure 59: Central-West Attractiveness Analysis, By Services
Figure 60: Central-West Attractiveness Analysis, By Product
Figure 61: Central-West Attractiveness Analysis, By Expression System
Figure 62: Central-West Attractiveness Analysis, By Company Size
Figure 63: Central-West Attractiveness Analysis, By Scale of Operation
Figure 64: Southeast Split By Services, 2023 (E)
Figure 65: Southeast Split By Product, 2023 (E)
Figure 66: Southeast Split By Expression System, 2023 (E)
Figure 67: Southeast Split By Company Size, 2023 (E)
Figure 68: Southeast Split By Scale of Operation, 2023 (E)
Figure 69: Southeast Historical Value (US$ million) Analysis, 2018 to 2022
Figure 70: Southeast Value (US$ million), 2023 to 2033 & Y-o-Y Growth Trend Analysis
Figure 71: Southeast Attractiveness Analysis, By Services
Figure 72: Southeast Attractiveness Analysis, By Product
Figure 73: Southeast Attractiveness Analysis, By Expression System
Figure 74: Southeast Attractiveness Analysis, By Company Size
Figure 75: Southeast Attractiveness Analysis, By Scale of Operation
Figure 76: South Split By Services, 2023 (E)
Figure 77: South Split By Product, 2023 (E)
Figure 78: South Split By Expression System, 2023 (E)
Figure 79: South Split By Company Size, 2023 (E)
Figure 80: South Split By Scale of Operation, 2023 (E)
Figure 81: South Historical Value (US$ million) Analysis, 2018 to 2022
Figure 82: South Value (US$ million), 2023 to 2033 & Y-o-Y Growth Trend Analysis
Figure 83: South Attractiveness Analysis, By Services
Figure 84: South Attractiveness Analysis, By Product
Figure 85: South Attractiveness Analysis, By Expression System
Figure 86: South Attractiveness Analysis, By Company Size
Figure 87: South Attractiveness Analysis, By Scale of Operation
